13 / 36
Dabrafenib + trametinib
No. at risk
Placebo
Months Since Randomization
Relapse-Free Survival,
%
100
90
80
70
60
50
40
30
20
10
0
0
12
24
30
42
54
6
18
36
48
60
Estimated cure rates
a
54% (95% CI, 49%-59%)
37% (95% CI, 32%-42%)
Cure-rate model for RFS
Dabrafenib + trametinib
Placebo
Kaplan-Meier curves for RFS
Dabrafenib + trametinib
Placebo
438
391
354
298
262
242
227
161
92
34
2
432
280
219
185
168
158
147
112
63
18
1
17%
difference
PRESENTED BY GV LONG AT ESMO 2018
a
Proportion of patients expected to remain relapse-free long term.
SLIDES ARE THE PROPERTY OF THE AUTHOR. PERMISSION REQUIRED FOR REUSE.
CURE-RATE MODEL RESULTS